Pier Capital LLC Buys 85,849 Shares of Certara, Inc. $CERT

Pier Capital LLC increased its stake in shares of Certara, Inc. (NASDAQ:CERT) by 11.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 840,449 shares of the company’s stock after purchasing an additional 85,849 shares during the quarter. Pier Capital LLC’s holdings in Certara were worth $7,404,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. First Horizon Corp bought a new position in shares of Certara during the 3rd quarter valued at approximately $30,000. Versant Capital Management Inc increased its position in shares of Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after purchasing an additional 1,153 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the last quarter. Global Retirement Partners LLC increased its position in shares of Certara by 45.0% during the 3rd quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock valued at $69,000 after purchasing an additional 1,749 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after purchasing an additional 4,930 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on CERT shares. TD Cowen reissued a “buy” rating on shares of Certara in a research report on Thursday, February 26th. Leerink Partners restated an “outperform” rating and set a $10.00 price objective on shares of Certara in a report on Thursday, February 26th. Craig Hallum cut Certara from a “buy” rating to a “hold” rating and set a $10.00 price objective for the company. in a report on Friday, February 27th. Wall Street Zen cut Certara from a “buy” rating to a “hold” rating in a report on Sunday, February 15th. Finally, KeyCorp dropped their price objective on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.44.

Certara Price Performance

CERT opened at $6.31 on Friday. The business has a fifty day moving average of $6.25 and a 200 day moving average of $8.11. Certara, Inc. has a 52-week low of $5.19 and a 52-week high of $13.88. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27. The stock has a market cap of $967.45 million, a P/E ratio of -631.00 and a beta of 1.53.

Certara (NASDAQ:CERT) last issued its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The firm had revenue of $103.65 million during the quarter, compared to analysts’ expectations of $103.23 million. During the same quarter in the prior year, the company posted $0.15 earnings per share. Certara’s quarterly revenue was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, sell-side analysts anticipate that Certara, Inc. will post 0.29 EPS for the current year.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.